After urging price concessions for pneumococcal disease vaccines in January and receiving a 20-cent-per-dose discount from Pfizer, Médecins Sans Frontières is sure to be unhappy with GlaxoSmithKline's response.
Amid the United States' battle with the current avian flu outbreak in poultry, the CDC on Wednesday announced plans to develop a vaccine to protect humans from a potential outbreak.
Australia's CSL will launch its new global flu vaccine business in early 2016, after it completes its $275 million acquisition of Novartis' flu vaccine unit.
PaxVax's typhoid vaccine, Vivotif, is licensed for sale in 27 countries. But the Redwood, CA-based company is looking to expand its presence, announcing on Wednesday a series of commercial partnerships and distribution agreements to ensure availability of Vivotif in Australia and Europe.
The need for cold-chain transportation has been a prominent barrier in making vaccines available to developing countries. A consortium led by Mymetics' Dutch subsidiary has just received €8.4 million to change that.
Chinese vaccines producer Sinovac laid out big R&D plans this week to test multiple candidates--one of which has the potential to challenge Big Pharma's standing in the country.
To cap off one of the least effective seasons for flu vaccines in recent memory, vaccine producer GlaxoSmithKline announced the recall of all remaining doses of a quadrivalent, affecting roughly 1.7 million jabs.
In December, Serum Institute of India reported victory in a Phase I trial of its powdered measles vaccine. But it may have to go back to the drawing board as results from a noninferiority trial reported Thursday showed that the powdered candidate was not as effective as the traditional injected vaccine.
A new analysis shows that healthcare systems can prevent throat cancer cases and save in long-term treatment costs by covering the HPV vaccine in young boys. Currently, Australia, Canada and the United States recommend the jab for boys, but only cover it for young girls.
In the latest development in the race for an Ebola vaccine, Merck and partner NewLink have taken their candidate to late-stage trials in Sierra Leone, the companies announced Tuesday.
Aduro Biotech is picking up in 2015 where it left off last year, riding momentum into an upsized $119 million IPO to fund its breakthrough pancreatic cancer immunotherapy combo CRS-207 and GVAX.
San Diego biotech Ichor Medical Systems stands to earn up to $85 million, plus royalties, if its new partnership with Johnson & Johnson's Janssen hits the right notes. The companies announced plans this week to develop DNA vaccines for hepatitis B using Ichor's TriGrid electroporation technology for clinical administration.
Two Maryland-based companies are racing to get a vaccine for respiratory syncytial virus to market--and one just picked up a regulatory boost.
In a win for HIV vaccine research, Duke University researchers have scored $20 million in grants from the National Institutes of Health to develop an HIV vaccine.
Pfizer has a new vaccines R&D head in Kathrin Jansen, who will begin at the post on June 1. Previously CSO of Pfizer's vaccine research and early development, Jansen will report to global R&D president Mikael Dolsten and work out of Pfizer's Pearl River, New York research site.
After the company's largest investment ever in the development of a vaccine, Sanofi Pasteur's dengue vaccine launch is ready for this year, and it'll be closely watched as the group introduces the jab in a manner reversed from traditional launches.
Back in November, U.K. heavyweight investor Neil Woodford invested $25 million in Northwest Biotherapeutics in the hope that its brain cancer candidate would turn up good Phase III results. Now, Woodford has thrown another $40 million behind the Bethesda, MD-based biotech as it continues to work through Phase III.
VBI Vaccines announced Monday that it is collaborating with Sanofi's vaccines unit to apply its Lipid Particle Vaccine to improve the stability of an undisclosed Sanofi Pasteur candidate. The terms of the agreement were not disclosed.
In the wake of its multibillion-dollar asset swap with Novartis, GlaxoSmithKline is doubling down on its vaccines focus. And it'll be doing that in Maryland, where it's establishing a new global R&D center.
While GlaxoSmithKline is still awaiting late-stage results for its shingles vaccine, HZ/su, Cowen & Co. analysts believe the vaccine may just be better than Merck's Zostavax.